First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline

Aung, Htin; Nyunt, Wint Wint; Fong, Yang; Cook, Gregory M.; Aung, Si Thu

doi:10.1093/cid/cix365

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, several new or repurposed drugs (i.e., bedaquiline, delamanid linezolid, and pretomanid) are drugs already available in Myanmar. The apparent absence of preexisting mutations that confer resistance to these drugs justifies their introduction into treatment regimens for drug-resistant TB in Myanmar, as per WHO recommendations (30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar

Aung¹,

Nyunt²,

Fong³

et al. 2021

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar

Aung¹,

Nyunt²,

Fong³

et al. 2021

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

“…This drug is an inhibitor of F1F0-ATP synthase of Mtb and blocks the production of ATP needed for growing bacteria [25]. It was approved under Food and Drug Administration’s accelerated-approval regulation in 2012 as a last resort drug for the treatment of patients with MDR-TB for whom treatment with known antibiotics regimens is ineffective [26,27]. Bedaquiline has also been approved by the European Medicines Agency in 2014 but trials are still ongoing to determine its long-term effect on patients [20].…”

Section: Tuberculosis: Overviewmentioning

confidence: 99%

Targeting the Serine Pathway: A Promising Approach against Tuberculosis?

Haufroid

Wouters

2019

Pharmaceuticals

View full text Add to dashboard Cite

Tuberculosis is still the leading cause of death by a single infectious agent. Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging. Only 10 new drugs are in clinical trials, and two of them have already demonstrated resistance. This paper gives an overview of current treatment options against tuberculosis and points out a promising approach of discovering new effective drugs. The serine production pathway is composed of three enzymes (SerA1, SerC and SerB2), which are considered essential for bacterial growth, and all of them are considered as a therapeutic drug target. Their crystal structure are described and essential regulatory domains pointed out. Sequence alignment with similar enzymes in other host would help to identify key residues to target in order to achieve selective inhibition. Currently, only inhibitors of SerB2 are described in the literature. However, inhibitors of human enzymes are discussed, and could be used as a good starting point for a drug discovery program. The aim of this paper is to give some guidance for the design of new hits for every enzyme in this pathway.

show abstract

“…This objective is particularly urgent in Myanmar, where tuberculosis (TB) is highly endemic ( 2 ) and drug-resistant TB is present through both acquired drug resistance and direct transmission. Unfortunately, the overwhelming number of TB cases precluded routine phenotypic drug susceptibility testing (DST) of first- or second-line drugs, so we began using whole-genome sequencing (WGS), which enabled us to more rapidly diagnose drug-resistant TB ( 3 ). Here, we briefly describe 2 cases of acquired antituberculosis drug resistance detected by WGS.…”

mentioning

confidence: 99%